Insulin resistance: a paradoxical protector against low-grade prostate cancer? Findings from the REDUCE trial
Postgraduate Medical Journal · 23.12.2025 · 102 (1203) · 84-85
DOI: 10.1093/postmj/qgaf047 ↗Kurz gefasst
Fachartikel in der Zeitschrift Postgraduate Medical Journal, online erschienen am 03.04.2025. Verfasst von Rupak Desai und 1 weiteren Autor:innen. Beteiligte Einrichtung: Independent Researcher, Atlanta, GA, United States. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 3 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
To the Editor, Elevated markers of insulin resistance, such as higher glucose levels and the triglyceride-glucose index, have been associated with poorer survival outcomes in prostate cancer patients, underscoring the impact of metabolic health on disease prognosis. The relationship between insulin resistance (IR) and prostate cancer (PC) remains a complex and debated topic [1, 2]. While some studies suggest that IR may increase the risk of PC, others propose a protective effect or no significant association. This inconsistency highlights a significant gap in our understanding of how metabolic factors influence prostate cancer development and progression. With a 4-year randomized study comparing dutasteride against placebo for PC prevention, the REDUCE trial presented a special chance to look at this relationship while minimizing the bias related to prostate-specific antigen (PSA)-driven screening. This study examined 5430 men who had an elevated PSA but a negative baseline biopsy and underwent mandated biopsies at 2 and 4 years. Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) based on fasting glucose and baseline fasting insulin levels evaluated IR [3]. Multivariable logistic and multinomial regression models were used to investigate associations between HOMA-IR (both continuous log-transformed and categorized by quartiles) and prostate cancer risk overall and stratified by tumor grade (low-grade [Gleason grade group 1] vs. high-grade [grade groups 2–5]), respectively. Higher insulin resistance, as measured by HOMA-IR, was linked to a lower risk of developing both overall and low-grade prostate cancer. On the continuous numerical scale, increase in each unit of log-transformed HOMA-IR was associated with an 11% reduction in overall PC risk (OR 0.89, 95% CI 0.80–0.99, P = 0.03). Similarly on the quartile categorical scale, higher HOMA-IR quartile showed association not only for OR but also for trend (P = 0.02) for inverse relations. Higher HOMA-IR, both continuous (OR 0.83, 95% CI 0.74–0.93, P < 0.001) and by quartile (4th vs. 1st quartile: OR 0.71, 95% CI 0.57–0.87, P = 0.0014), was associated with a significantly decreased risk of low-grade prostate cancer (P-trend
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Independent Researcher, Atlanta, GA, United States.
- Division of Hematology/Oncology, University of Iowa Hospitals and Clinics, Iowa City, United States.
Zitieren
APA
Desai, R., & Jain, A. (2025). Insulin resistance: a paradoxical protector against low-grade prostate cancer? Findings from the REDUCE trial. Postgraduate Medical Journal, 102(1203), 84-85. https://doi.org/10.1093/postmj/qgaf047
Vancouver
Desai R, Jain A. Insulin resistance: a paradoxical protector against low-grade prostate cancer? Findings from the REDUCE trial. Postgraduate Medical Journal. 2025;102(1203):84-85. doi:10.1093/postmj/qgaf047
BibTeX
@article{Desai2025,
author = {Desai, Rupak and Jain, Akhil},
title = {Insulin resistance: a paradoxical protector against low-grade prostate cancer? Findings from the REDUCE trial},
journal = {Postgraduate Medical Journal},
year = {2025},
volume = {102},
number = {1203},
pages = {84--85},
doi = {10.1093/postmj/qgaf047}
}
EUVIMED